Viking Therapeutics (VKTX) Notes Payables (2014 - 2018)

Viking Therapeutics (VKTX) has 5 years of Notes Payables data on file, last reported at $3.7 million in Q1 2018.

• For the quarter ending Q1 2018, Notes Payables changed N/A year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2018 stood at $3.7 million (changed N/A YoY), and the FY2017 full-year result was $3.5 million, up 5.55% from the prior year.
• Notes Payables climbed to $3.7 million in Q1 2018, from $3.5 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $3.7 million in Q1 2018 to a low of $304274.0 in Q4 2014.
• A 5-year average of $2.4 million and a median of $2.8 million in 2016 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables surged 47.89% in 2016 and increased 5.55% in 2017, its largest moves.
• Tracing VKTX's Notes Payables over 5 years: stood at $304274.0 in 2014, then soared by 528.06% to $1.9 million in 2015, then surged by 71.09% to $3.3 million in 2016, then gained by 5.55% to $3.5 million in 2017, then gained by 7.82% to $3.7 million in 2018.
• Business Quant data shows VKTX's Notes Payables at $3.7 million in Q1 2018, $3.5 million in Q4 2017, and $3.2 million in Q3 2017.